Diagnostic Ventures is proud to work with leading PhD researchers at Brigham Young University. Our technology has been in development since 2016 and currently targets the identification of sepsis-causing pathogens within 20 minutes without a blood culture.
Originally funded by a $5.2M grant from the National Institute of Health.
This product is under development and not approved for sale. This product is not yet FDA approved.
